#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Acute myeloid leukaemia Neoplasm malignant Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Ovarian cancer Colorectal cancer Hepatocellular carcinoma Dermatitis atopic Dementia Alzheimer's type Asthma Type 2 diabetes mellitus Breast cancer metastatic Non-small cell lung cancer metastatic More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Acute graft versus host disease in skin NTRK gene fusion overexpression Hepatocellular carcinoma Conjunctivitis allergic Hidradenitis Arrhythmogenic right ventricular dysplasia Hereditary spastic paraplegia Liposarcoma Polycystic liver disease Chronic graft versus host disease in intestine Eosinophilic oesophagitis Autologous haematopoietic stem cell transplant Pericarditis Glycogen storage disease type I Retinal artery occlusion More trials…

    Learn about Rare Diseases

    Nodal marginal zone B-cell lymphoma – Diagnostics Mantle cell lymphoma stage III Metachromatic leukodystrophy – Trials in Disease Leukoencephalopathy – Diagnostics Angiosarcoma – Diagnostics Turner’s syndrome Sjogren’s syndrome Synovial sarcoma Sarcoma – Basic Information Combined immunodeficiency – Life with Disease More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Dacarbazine Citrate Rupatadine Maridebart Cafraglutide Hypromellose Deoxyribonucleic Acid Poa Pratensis Pollen Extract Dazodalibep Baricitinib Ampicillin Ly3484356 Cariprazine Ecoo4 Namodenoson SAROGLITAZAR HEMIMAGNESIUM ANGIOTENSIN II Diacerein Triptorelin Vibosameran Hydroxi-Methionine Calcium Ttx-030 More therapies…

    Learn about Your Condition

    Pyoderma Biotinidase deficiency Drug use disorder Osteoarthritis Schizoaffective disorder Erythema Laparotomy Pelizaeus-Merzbacher disease Neurofibromatosis White matter lesion Gastrointestinal melanoma Dry mouth Endometrial stromal sarcoma Arrhythmia Hypogonadism male More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden
  1. Clinicaltrials.eu/
  2. Bacs-Kiskun Varmegyei Oktatokorhaz

Bacs-Kiskun Varmegyei Oktatokorhaz

Nyiri Ut 38, Kecskemet, 6000, Hungary

Want to learn more about this study or check if you can participate? Contact us.

  • Gedatolisib plus drug combination for HR‑positive, HER2‑negative advanced breast cancer patients whose disease progressed after CDK4/6 inhibitor therapy

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Hormone receptor positive HER2 negative breast cancer
    • Hormone receptor positive breast cancer
    Investigated Drugs:
    • Alpelisib
    • Dexamethasone
    • Fulvestrant
    Austria Belgium Bulgaria Czechia France Germany +6

  • Efficacy Comparison of Zanzalintinib (XL092) and Pembrolizumab Versus Pembrolizumab Monotherapy in PD-L1 Positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

    Not recruiting

    4 1 1 1
    Investigated Diseases:
    • Squamous cell carcinoma of head and neck
    Investigated Drugs:
    • N-(4-Fluorophenyl)-N-(4-((7-Methoxy-6-(Methylcarbamoyl)Quinolin-4- Yl)Oxy)Phenyl)Cyclopropane-1,1-Dicarboxamide
    • Pembrolizumab
    Austria Belgium Bulgaria Czechia France Germany +7

  • A Study of Camizestrant Compared to Standard Hormone Therapy for Patients with ER-Positive HER2-Negative Early Breast Cancer After Initial Treatment

    Not recruiting

    3 1 1 1
    Investigated Drugs:
    • Abemaciclib
    • Anastrozole
    • Camizestrant
    Austria Belgium Bulgaria Croatia Czechia Estonia +10

  • Testing Drug Combinations with GSK4381562A, GSK6097608, GSK4428859 and Dostarlimab in Patients with PD-L1 Positive Head and Neck Cancer That Has Spread or Returned

    Not recruiting

    2 1 1 1
    Investigated Diseases:
    • Squamous cell carcinoma of head and neck
    Investigated Drugs:
    • Dostarlimab
    • Gsk4381562A
    • Gsk6097608
    Denmark Finland France Germany Greece Hungary +6

  • A study testing aprepitant gel for treating skin rash in cancer patients receiving epidermal growth factor receptor inhibitor therapy

    Not recruiting

    2 1
    Investigated Drugs:
    • Aprepitant
    Hungary Poland Spain

  • Study of Ruxolitinib Cream for Children and Adolescents Ages 6-17 with Moderate Atopic Dermatitis Who Did Not Respond Well to Standard Treatments

    Not recruiting

    3 1
    Investigated Drugs:
    • Ruxolitinib
    Belgium France Germany Hungary Italy Poland +1

  • Study on the Safety and Effectiveness of Clesrovimab and Palivizumab for Preventing Severe RSV in Infants and Children at High Risk

    Not recruiting

    3 1 1
    Investigated Drugs:
    • CLESROVIMAB
    • Palivizumab
    • Sodium Chloride
    Czechia Finland France Germany Greece Hungary +3

  • Study on the Effectiveness and Safety of Remibrutinib for Adults with Moderate to Severe Hidradenitis Suppurativa

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Hidradenitis
    Investigated Drugs:
    • Clindamycin Hydrochloride
    • Remibrutinib
    • SALICYLIC ACID
    Austria Belgium Czechia France Germany Greece +4

  • Study on the Effectiveness and Safety of JNJ-77242113 Compared to Placebo and Ustekinumab for Patients with Moderate to Severe Plaque Psoriasis

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Psoriasis
    Investigated Drugs:
    • Jnj-77242113
    • Ustekinumab
    Austria Belgium Denmark Germany Hungary Poland +2

  • Study on Long-term Safety and Effectiveness of ESK-001 for Patients with Moderate to Severe Plaque Psoriasis

    Not recruiting

    3 1
    Investigated Drugs:
    • Envudeucitinib
    Austria Belgium Bulgaria Czechia Estonia France +7
Previous Page
1 … 4 5 6 7 8 … 13
Next Page

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!